Welcome, Friend!

It looks like you're new here. If you want to get involved, click one of these buttons!

Veritas-Health LLC has recently released patient forums to our Arthritis-Health web site.

Please visit http://www.arthritis-health.com/forum

There are several patient story videos on Spine-Health that talk about Arthritis. Search on Patient stories
Protect anonymity
We strongly suggest that members do not include their email addresses. Once that is published , your email address is available to anyone on the internet , including hackers.

All discussions and comments that contain an external URL will be automatically moved to the spam queue. No external URL pointing to a medical web site is permitted. Forum rules also indicate that you need prior moderator approval. If you are going to post an external URL, contact one of the moderators to get their approval.
Attention New Members
Your initial discussion or comment automatically is sent to a moderator's approval queue before it can be published.
There are no medical professionals on this forum side of the site. Therefore, no one is capable or permitted to provide any type of medical advice.
This includes any analysis, interpretation, or advice based on any diagnostic test

New NSAID Nasal Spray Approved

happyHBmomhhappyHBmom Posts: 2,070
edited 06/11/2012 - 8:44 AM in Pain Medications
FDA has approved a new nasal application of a very strong NSAID generally given intraveneously in hospital settings:

Generic Name: ketorolac tromethamine nasal spray
Date of Approval: May 14, 2010
Company: Roxro Pharma, Inc.

Treatment for: Pain
FDA Approves Sprix

The U.S. Food and Drug Administration (FDA) has approved Sprix (ketorolac tromethamine) Nasal Spray, for the short-term (up to 5 days) management of acute moderate to moderately severe pain that requires analgesia at the opioid level.

Sprix is a prescription intranasal formulation of the analgesic ketorolac, a non-steroidal anti-inflammatory drug (NSAID), designed to provide ambulatory patients with a convenient, potent, and fast-acting option for acute moderate to moderately severe pain relief.

Ketorolac tromethamine is a frequently administered non-narcotic injectable analgesic for moderately severe pain in U.S. hospitals today. The approval of Sprix provides acute pain outpatients with a non-narcotic and easy-to-administer alternative to commonly prescribed opioids.
Highlights of Sprix Prescribing Information

These highlights do not include all of the information needed to use Sprix safely and effectively. See full prescribing information for Sprix.

Warning: Limitations of Use, Gastrointestinal, Bleeding, Cardiovascular, and Renal Risk

See full prescribing information for complete boxed warning.

* Limitations of Use – The total duration of use of Sprix and other ketorolac formulations should not exceed 5 days.
* Gastrointestinal (GI) Risk – Ketorolac can cause peptic ulcers, GI bleeding, and/or perforation of the stomach or intestines, which can be fatal.
* Sprix is contraindicated in patients with peptic ulcer disease or history of GI bleeding.
* Bleeding Risk – Sprix inhibits platelet function and is contraindicated in patients with suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, or high risk of bleeding.
* Cardiovascular (CV) Risk – NSAIDs may cause an increased risk of serious CV thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with CV disease or risk factors for CV disease may be at greater risk.
* Sprix is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
* Renal risk – Sprix is contraindicated in patients with advanced renal impairment and in patients at risk for renal failure due to volume depletion.

Sprix Indications and Usage

Sprix is indicated for short term (up to 5 days) management of moderate to moderately severe pain.
Sign In or Register to comment.